MPLT insider buying and SEC filings, explained
MapLight Therapeutics, Inc. · CIK 1770069
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Alvarado Therapeutics, Inc.
Insider activity in the last 12 months
Bought
$66.2M
Insiders who bought
4
Sold (not marked 10b5-1)
$10.2M
Planned sales (10b5-1)
$20.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 15, 2026 | Sale | Anatol Kreitzer (Chief Discovery Officer) sold 12,248 shares at $7.84 ($96K). Holdings down 7% to 168,678 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 16, 2026, 5:00 PM ET |
| Oct 15, 2026 | Sale | Jonathan Gillis (CFO) sold 10,167 shares at about $8.08 ($82K). Holdings down 7% to 142,315 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 16, 2026, 5:00 PM ET |
| Oct 15, 2026 | Sale | James Woodruff Lillie (Chief Scientific Officer) sold 11,513 shares at about $8.08 ($93K). Holdings down 5% to 198,597 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 16, 2026, 5:00 PM ET |
| Oct 15, 2026 | Sale | Kristopher Hanson (General Counsel) sold 9,020 shares at about $8.08 ($73K). Holdings down 7% to 128,024 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 16, 2026, 5:00 PM ET |
| Oct 15, 2026 | Sale | Erin Pennock Foff (Chief Medical Officer) sold 15,355 shares at about $8.08 ($124K). Holdings down 5% to 296,906 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 16, 2026, 5:00 PM ET |
| Oct 15, 2026 | Sale | Christopher A. Kroeger (CEO and Director) sold 73,691 shares at about $8.08 ($595K). Holdings down 6% to 1,195,909 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 16, 2026, 5:00 PM ET |
| Sep 16, 2026 | Planned (10b5-1) | Kristopher Hanson (General Counsel) sold 16,509 shares at about $11.67 ($193K), marked as a 10b5-1 plan trade. Holdings down 11% to 137,044 shares. | SEC filing Filed Sep 18, 2026 |
| Aug 14, 2026 | Other purchase | Catalyst4, Inc. (10% owner) bought 2,928,686 Warrants (right to buy) indirectly at $11.38 ($33.3M), reported as a purchase (code P). New position of 2,928,686 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 18, 2026 |
| Aug 14, 2026 | Purchase (code P) | Catalyst4, Inc. (10% owner) bought 4,400,000 shares indirectly at $11.38 ($50.1M), reported as a purchase (code P). Indirect holdings up 21% to 25,306,689 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 18, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | James Woodruff Lillie (Chief Scientific Officer) sold 22,082 shares at about $12.54 ($277K), marked as a 10b5-1 plan trade. Holdings down 10% to 202,380 shares. | SEC filing Filed Aug 4, 2026 |
| Jul 28–30, 2026 | Purchase (code P) | Catalyst4, Inc. (10% owner) bought 1,209,225 shares indirectly between Jul 28 and Jul 30 at about $12.66 ($15.3M), reported as a purchase (code P). Indirect holdings up 6% to 20,906,689 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 30, 2026 |
| Jul 28, 2026 | Purchase (code P) | Troy Cox (Director) bought 15,620 shares indirectly (by trust) at about $9.52 ($149K), reported as a purchase (code P). New position of 15,620 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 28, 2026 |
| Jul 15–17, 2026 | Planned (10b5-1) | Anatol Kreitzer (Chief Discovery Officer) sold 36,284 shares between Jul 15 and Jul 17 at about $37.09 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 17% to 174,906 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 15–17, 2026 | Planned (10b5-1) | Jonathan Gillis (CFO) sold 36,979 shares between Jul 15 and Jul 17 at about $37.12 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 20% to 144,240 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 15–17, 2026 | Planned (10b5-1) | Erin Pennock Foff (Chief Medical Officer) sold 47,158 shares between Jul 15 and Jul 17 at about $36.78 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 14% to 298,901 shares. | SEC filing Filed Jul 17, 2026 |
| Jul 15–17, 2026 | Sale | Kristopher Hanson (General Counsel) sold 16,508 shares between Jul 15 and Jul 17 at about $36.82 ($608K). Holdings down 10% to 145,823 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 17, 2026 |
| Jul 15–17, 2026 | Sale | James Woodruff Lillie (Chief Scientific Officer) sold 18,267 shares between Jul 15 and Jul 17 at about $36.88 ($674K). Holdings down 8% to 224,462 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 17, 2026 |
| Jul 15–17, 2026 | Sale | Christopher A. Kroeger (CEO and Director) sold 147,639 shares between Jul 15 and Jul 17 at about $36.87 ($5.4M). Holdings down 11% to 1,246,455 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 17, 2026 |
| May 18, 2026 | Planned (10b5-1) | Christopher A. Kroeger (CEO and Director) sold 118,235 shares at about $27.19 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 8% to 1,394,094 shares. | SEC filing Filed May 18, 2026 |
| May 11, 2026 | Planned (10b5-1) | Kristopher Hanson (General Counsel) sold 13,917 shares at about $30.13 ($419K), marked as a 10b5-1 plan trade. Holdings down 8% to 162,331 shares. | SEC filing Filed May 11, 2026 |
| May 7, 2026 | Planned (10b5-1) | Erin Pennock Foff (Chief Medical Officer) sold 4,438 shares at about $28.54 ($127K), marked as a 10b5-1 plan trade. Holdings down 1% to 346,059 shares. | SEC filing Filed May 11, 2026 |
| May 7, 2026 | Planned (10b5-1) | James Woodruff Lillie (Chief Scientific Officer) sold 721 shares at about $28.28 ($20K), marked as a 10b5-1 plan trade. Holdings down <1% to 242,729 shares. | SEC filing Filed May 11, 2026 |
| May 7–11, 2026 | Planned (10b5-1) | Christopher A. Kroeger (CEO and Director) sold 68,491 shares between May 7 and May 11 at about $28.47 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 4% to 1,512,329 shares. | SEC filing Filed May 11, 2026 |
| May 4–6, 2026 | Planned (10b5-1) | Vishwas Setia (CFO) sold 36,371 shares between May 4 and May 6 at about $28.17 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 9% to 356,256 shares. | SEC filing Filed May 6, 2026 |
| May 4–6, 2026 | Planned (10b5-1) | Erin Pennock Foff (Chief Medical Officer) sold 50,280 shares between May 4 and May 6 at about $28.39 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 13% to 350,497 shares. | SEC filing Filed May 6, 2026 |
| May 4, 2026 | Planned (10b5-1) | Kristopher Hanson (General Counsel) sold 13,917 shares at about $27.89 ($388K), marked as a 10b5-1 plan trade. Holdings down 7% to 176,248 shares. | SEC filing Filed May 6, 2026 |
| May 4–6, 2026 | Planned (10b5-1) | James Woodruff Lillie (Chief Scientific Officer) sold 51,707 shares between May 4 and May 6 at about $28.40 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 18% to 243,450 shares. | SEC filing Filed May 6, 2026 |
| May 4–6, 2026 | Planned (10b5-1) | Christopher A. Kroeger (CEO and Director) sold 49,744 shares between May 4 and May 6 at about $28.39 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 3% to 1,580,820 shares. | SEC filing Filed May 6, 2026 |
| Apr 27, 2026 | Planned (10b5-1) | Anatol Kreitzer (Chief Discovery Officer) sold 45,422 shares at about $29.66 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 18% to 211,190 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 27–28, 2026 | Planned (10b5-1) | Jonathan Gillis (CAAO and PAO) sold 69,835 shares between Apr 27 and Apr 28 at about $29.89 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 28% to 181,219 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 15–16, 2026 | Sale | Vishwas Setia (CFO) sold 2,922 shares between Apr 15 and Apr 16 at about $26.89 ($79K). Holdings down 1% to 392,627 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 15, 2026 | Sale | Anatol Kreitzer (Chief Discovery Officer) sold 3,316 shares at about $26.61 ($88K). Holdings down 1% to 256,612 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 15–16, 2026 | Sale | Erin Pennock Foff (Chief Medical Officer) sold 3,213 shares between Apr 15 and Apr 16 at about $27.03 ($87K). Holdings down 1% to 400,777 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Robert C. Malenka (Director) sold 8,593 shares at about $26.90 ($231K), marked as a 10b5-1 plan trade. Holdings down 3% to 316,466 shares. | SEC filing Filed Apr 17, 2026 |
| Apr 15–16, 2026 | Sale | Kristopher Hanson (General Counsel) sold 1,827 shares between Apr 15 and Apr 16 at about $26.89 ($49K). Holdings down 1% to 190,165 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 15–16, 2026 | Sale | James Woodruff Lillie (Chief Scientific Officer) sold 4,513 shares between Apr 15 and Apr 16 at about $27.16 ($123K). Holdings down 2% to 295,157 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 15, 2026 | Sale | Jonathan Gillis (CAAO and PAO) sold 3,590 shares at about $26.61 ($96K). Holdings down 1% to 251,054 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Apr 15–16, 2026 | Sale | Christopher A. Kroeger (CEO and Director) sold 19,187 shares between Apr 15 and Apr 16 at about $27.16 ($521K). Holdings down 1% to 1,630,564 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 17, 2026 |
| Feb 20–24, 2026 | Sale | Robert C. Malenka (Director) sold 14,195 shares between Feb 20 and Feb 24 at about $18.34 ($260K). Holdings down 4% to 325,059 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Feb 18–20, 2026 | Purchase (code P) | George Pavlov (Director) bought 25,000 shares between Feb 18 and Feb 20 at about $17.65 ($441K), reported as a purchase (code P). New position of 25,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Feb 13, 2026 | Sale | Robert C. Malenka (Director) sold 12,116 shares at about $18.21 ($221K). Holdings down 3% to 339,254 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 10–11, 2026 | Sale | Robert C. Malenka (Director) sold 6,863 shares between Feb 10 and Feb 11 at about $18.12 ($124K). Holdings down 2% to 351,370 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 12, 2026 |
| Feb 10, 2026 | Purchase (code P) | Timothy John Garnett (Director) bought 14,124 shares indirectly at about $17.89 ($253K), reported as a purchase (code P). New position of 14,124 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 12, 2026 |
| Feb 2–3, 2026 | Sale | Robert C. Malenka (Director) sold 7,040 shares between Feb 2 and Feb 3 at about $18.02 ($127K). Holdings down 2% to 358,233 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Jan 28–30, 2026 | Sale | Robert C. Malenka (Director) sold 34,398 shares between Jan 28 and Jan 30 at about $18.49 ($636K). Holdings down 9% to 365,273 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 30, 2026 |
26 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$65.5M in purchases since Jul 28, 2026 · Purchases traded Jul 28, 2026 to Aug 14, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Troy Cox (Director) | $149K | Jul 28, 2026 | SEC filing |
| Catalyst4, Inc. (10% owner) | $15.3M | Jul 30, 2026 | SEC filing |
| Catalyst4, Inc. (10% owner) | $50.1M | Aug 14, 2026 | SEC filing |
2 insiders bought in 30 days
$694K in purchases since Feb 10, 2026 · Purchases traded Feb 10, 2026 to Feb 20, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Timothy John Garnett (Director) | $253K | Feb 10, 2026 | SEC filing |
| George Pavlov (Director) | $441K | Feb 20, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow MPLT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.